Search

Your search keyword '"Quiroga, Borja"' showing total 28 results
Start Over Author "Quiroga, Borja" Publication Year Range This year
28 results on '"Quiroga, Borja"'

3. Consensus on the approach to hydrosaline overload in acute heart failure. SEMI/SEC/S.E.N. recommendations

Author

Llàcer, Pau, Romero, Gregorio, Trullàs, Joan Carles, de la Espriella, Rafael, Cobo, Marta, Quiroga, Borja, Casado, Jesús, Slon-Roblero, María F., Morales-Rull, José Luis, Morgado, José Ignacio, Ortiz, Alberto, Formiga, Francesc, Melendo-Viu, María, de Sequera, Patricia, Recio, Alejandro, Díez, Javier, Manzano, Luis, and Núñez, Julio

Published
2024
Full Text
View/download PDF

4. Consenso sobre el abordaje de la sobrecarga hidrosalina en insuficiencia cardiaca aguda. Recomendaciones SEMI/SEC/S.E.N.

Author

Llàcer, Pau, Romero, Gregorio, Trullàs, Joan Carles, de la Espriella, Rafael, Cobo, Marta, Quiroga, Borja, Casado, Jesús, Slon-Roblero, María F., Morales-Rull, José Luis, Morgado, José Ignacio, Ortiz, Alberto, Formiga, Francesc, Melendo-Viu, María, de Sequera, Patricia, Recio, Alejandro, Díez, Javier, Manzano, Luis, and Núñez, Julio

Published
2024
Full Text
View/download PDF

9. Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study

Author

Eugenia García Montemayor, Victoria, Salgueira Lazo, Mercedes, Mazuecos Blanca, Auxiliadora, Jiménez Salcedo, Tamara, José Espigares Huete, María, Araceli Jiménez Vibora, Elena, Álamo Caballero, Concepción, Banegas Deras, Eduardo J., Alonso Bethencourt, Alejandro, Rodríguez García, Alejandra, Fernández Granados, Saulo, Fernández Fresnedo, Gema, Calle García, Leonardo, Martín García, Jesús, Estifan Kasabji, Jorge, Jesús Izquierdo, María, Mouzo Mirco, Ricardo, García Agudo, Rebeca, de Arriba de la Fuente, Gabriel, Facundo Molas, Carme, Xipell Font, Marc, Yugueros González, Alejandra, Antóns, Paula, Ibernon Vilaro, Meritxell, de la Fuente Fernández, Vanessa, González Galván, Yussel, Cabezas, Antonio, Castro Alonso, Cristina, Juan García, Isabel, Garín Cascales, Eduardo, Sebastiá Morant, Josepa, Luna Complejo, Enrique, María Díaz Campillejo, Rosa, González Sanchidrián, Silvia, Cao Vilariño Complejo, Mercedes, Sierra Carpio, Milagros, Ortega Díaz, Mayra, Sánchez Hernández, Rosa, Ossorio González, Marta, Vega Martínez, Almudena, Teresa López Picasso, María, Goma, Elena, Giorgi, Martín, Martínez Miguel, Patricia, Gutiérrez Martínez, Eduardo, Paraíso Cuevas, Vicente, Echarri, Rocío, Martínez, Víctor, Pérez Arnedo, Mario, Juliana Castañeda Infante, Laura, Antonio Menacho Miguel, Jose, Blasco, Miquel, Quiroga, Borja, García-Aznar, José M., Castro-Alonso, Cristina, Fernández-Granados, Saulo J., Luna, Enrique, Ossorio, Marta, Izquierdo, María Jesús, Sanchez-Ospina, Didier, Castañeda-Infante, Laura, Mouzo, Ricardo, Cao, Mercedes, Besada-Cerecedo, María L., Pan-Lizcano, Ricardo, Torra, Roser, Ortiz, Alberto, and de Sequera, Patricia

Published
2024
Full Text
View/download PDF

13. Practical Approaches to the Management of Cardiorenal Disease Beyond Congestion

Author

Blazquez-Bermejo, Zorba, primary, Quiroga, Borja, additional, Casado, Jesús, additional, de la Espriella, Rafael, additional, Trullàs, Joan Carles, additional, Romero-González, Gregorio, additional, Rubio-Gracia, Jorge, additional, Díez, Javier, additional, Núñez, Julio, additional, de Sequera, Patricia, additional, Recio-Mayoral, Alejandro, additional, Pérez-Silvestre, José, additional, and Cobo Marcos, Marta, additional

Published
2024
Full Text
View/download PDF

15. Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation

Author

Bouthelier, Antonio, Fernández- Arroyo, Lucía, Mesa Ciller, Claudia, Cibrian, Danay, Martín Cofreces, Noa Beatriz, Castillo González, Raquel, Calero Calero, Macarena, Herráez Aguilar, Diego, Guajardo Grence, Andrea, Pacheco, Ana María, Marcos Jiménez, Ana, Quiroga, Borja, Morado, Marta, Monroy Muñoz, Francisco, Muñoz Calleja, Cecilia, Sánchez Madrid, Francisco, Urrutia, Andrés A, Aragonés, Julián, Bouthelier, Antonio, Fernández- Arroyo, Lucía, Mesa Ciller, Claudia, Cibrian, Danay, Martín Cofreces, Noa Beatriz, Castillo González, Raquel, Calero Calero, Macarena, Herráez Aguilar, Diego, Guajardo Grence, Andrea, Pacheco, Ana María, Marcos Jiménez, Ana, Quiroga, Borja, Morado, Marta, Monroy Muñoz, Francisco, Muñoz Calleja, Cecilia, Sánchez Madrid, Francisco, Urrutia, Andrés A, and Aragonés, Julián

Abstract

Inhibition of the heterodimeric amino acid carrier SLC7A5/SLC3A2 (LAT1/CD98) has been widely studied in tumor biology but its role in physiological conditions remains largely unknown. Here we show that the SLC7A5/SLC3A2 heterodimer is constitutively present at different stages of erythroid differentiation but absent in mature erythrocytes. Administration of erythropoietin (EPO) further induces SLC7A5/SLC3A2 expression in circulating reticulocytes, as it also occurs in anemic conditions. Although Slc7a5 gene inactivation in the erythrocyte lineage does not compromise the total number of circulating red blood cells (RBCs), their size and hemoglobin content are significantly reduced accompanied by a diminished erythroblast mTORC1 activity. Furthermore circulating Slc7a5-deficient reticulocytes are characterized by lower transferrin receptor (CD71) expression as well as mitochondrial activity, suggesting a premature transition to mature RBCs. These data reveal that SLC7A5/SLC3A2 ensures adequate maturation of reticulocytes as well as the proper size and hemoglobin content of circulating RBCs., Depto. de Química Física, Fac. de Ciencias Químicas, TRUE, pub

Published
2024

16. Estrategias de prevención y tratamiento de la infección por SARS-CoV-2 (Severe Acute Respiratory Coronavirus 2)en pacientes con enfermedad renal crónica: revisión de la literatura

Author

Marques Vida, María, Muñez Rubio, Elena, Quiroga, Borja, Montejano, Rocío, Morales, Enrique, and Candel, Francisco Javier

Abstract

La COVID-19 ha demostrado ser especialmente agresiva con los pacientes con enfermedad renal crónica (ERC). La menor tasa de respuesta inmunológica y la mayor facilidad para la progresión a formas graves de enfermedad ha propiciado este hecho, que se ha mantenido en la era posvacunal de la pandemia. Paradójicamente, la ERC ha sido excluida de la mayoría de los ensayos clínicos de las principales herramientas terapéuticas desarrolladas frente a SARS-CoV-2. Sin embargo, se ha ido reuniendo experiencia de uso de estos fármacos en distintos estadios de la ERC que avala su uso con garantías de eficacia y seguridad.

Published
2024
Full Text
View/download PDF

17. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study.

Author

Quiroga, Borja, Ortiz, Alberto, Núñez, Sara, Kislikova, Maria, González Sanchidrián, Silvia, Broseta, José Jesús, Albines, Zoila Stany, Escamilla Cabrera, Beatriz, Rivero Viera, Yaiza, Rodriguez Santarelli, David, Salanova Villanueva, Laura, Lopez Rodriguez, Francisca, Cancho Castellano, Barbara, Ibáñez Cerezon, María, Gutierrez Rivas, Carmen Patricia, Aresté, Nuria, Campos Gutiérrez, Belén, Ródenas Gálvez, Ana, Glucksmann Pizá, Maria Constanza, and Balda Manzanos, Sagrario

Published
2024
Full Text
View/download PDF

18. Selective glomerular hypofiltration syndrome.

Author

Quiroga, Borja, Ortiz, Alberto, and Díez, Javier

Subjects
*CARDIOVASCULAR diseases, *CYSTATIN C, *GLOMERULAR filtration rate, *SMALL molecules, *SYNDROMES
Abstract

The estimated glomerular filtration rate (eGFR) provides insight into cardiovascular disease (CVD) risk stratification and proactive management. Accumulating evidence suggests that combining eGFR calculated from serum cystatin C (eGFRcys) and from serum creatinine (eGFRcrea) improves CVD risk stratification over eGFRcrea alone. The term selective glomerular hypofiltration syndrome (SGHS) or shrunken pore syndrome has been proposed to define an eGFRcys:eGFRcrea ratio <1, which is hypothesized to result from a reduced glomerular filtration of 5- to 30-kDa molecules as compared with smaller molecules. SGHS may be identified in people with normal or reduced measured GFR, but the prevalence depends on the cut-off value of the eGFRcys:eGFRcrea ratio used, which is not yet standardized. SGHS is strongly associated with increased CVD and mortality risks and it may offer an opportunity to expand our understanding of the mechanisms linking GFR disorders with CVD risk (e.g. an altered plasma proteome), which may guide treatment decisions. However, muscle wasting may also contribute to a reduced eGFRcys:eGFRcrea ratio and there are open questions regarding the pathophysiology of a reduced eGFRcys:eGFRcrea ratio, the reference cut-off values of the ratio to define the syndrome and its clinical implications. We now critically review the SGHS concept, its pathophysiological basis and links to CVD and the potential consequences for clinical practice and propose a research agenda. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Consensus document on palliative care in cardiorenal patients.

Author

Bonanad, Clara, Buades, Juan M., Pablo Leiva, Juan, De la Espriella, Rafael, Cobo Marcos, Marta, Núñez, Julio, García-Llana, Helena, Facila, Lorenzo, Sánchez, Rosa, Rodríguez-Osorio, Laura, Alonso-Babarro, Alberto, Quiroga, Borja, Bompart Berroteran, Daznia, Rodríguez, Carmen, Maidana, Daniela, and Díez, Javier

Published
2024
Full Text
View/download PDF

21. CONSULTA MÉDICA.

Author

MARÍN, FRANCISCO, SÁNCHEZ FERRO, ÁLVARO, QUIROGA, BORJA, and CHINER, EUSEBI

Published
2024

24. Uso de nuevas terapias hipolipemiantes en la práctica clínica. Consenso SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N

Author

Vivas, David, Escobar, Carlos, Cordero, Alberto, Fernández-Olmo, Rosa, Oterino, Armando, Blanco-Echevarría, Agustín, Botana, Manuel, Escribano, Daniel, Mar Freijo, María del, Martínez-Losas, Pedro, Pascual, Vicente, Quiroga, Borja, Sánchez-Peinador, Carmen, Torres-Fonseca, Mónica, Freixa-Pamias, Román, Barrios, Vivencio, and Barón-Esquivias, Gonzalo

Abstract

A pesar de que en los últimos años se ha avanzado en el control de los factores de riesgo vascular, los datos de vida real muestran cómo solo un porcentaje bajo de pacientes consiguen alcanzar concentraciones de colesterol ligado a lipoproteínas de baja densidad definidos. Recientemente, han surgido nuevas dianas terapéuticas en el campo de los fármacos hipolipemiantes que pueden ayudar a la consecución de los objetivos terapéuticos recomendados por las guías de práctica clínica y, por consiguiente, reducir la incidencia de eventos vasculares adversos. No obstante, existen ciertas incertidumbres en la práctica clínica acerca del momento oportuno de su prescripción y en qué pacientes utilizarlas, en comparación con las terapias «clásicas» como las estatinas o el ezetimibe. Debido a este complejo escenario se propone este documento de consenso, certificado por las sociedades científicas que más frecuentemente se enfrentan al paciente con enfermedad aterosclerótica (SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.), y cuyo objetivo es ayudar de una forma práctica y con la evidencia científica actual a la utilización de las nuevas terapias hipolipemiantes en diferentes escenarios clínicos.

Published
2024
Full Text
View/download PDF

25. Toxinas unidas a proteínas: valor añadido en su eliminación con altos volúmenes convectivos

Author

Abad, Soraya, Vega, Almudena, Quiroga, Borja, Arroyo, David, Panizo, Nayara, Reque, Javier Eduardo, and López-Gómez, Juan Manuel

Abstract

La enfermedad renal crónica tiene mayor riesgo de eventos cardiovasculares. En los últimos años, han ido adquiriendo mayor importancia las toxinas unidas a proteínas, que han sido asociadas a mayor morbimortalidad y que se caracterizan por la dificultad para su depuración en diálisis. El objetivo de este estudio es valorar la influencia de altos volúmenes convectivos en HDF-OL posdilucional sobre la eliminación de medianas moléculas, pequeñas moléculas y moléculas unidas a proteínas.

Published
2024
Full Text
View/download PDF

27. Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study

Author

Blasco, Miquel, Quiroga, Borja, García-Aznar, José M., Castro-Alonso, Cristina, Fernández-Granados, Saulo J., Luna, Enrique, Fernández Fresnedo, Gema, Ossorio, Marta, Izquierdo, María Jesús, Sanchez-Ospina, Didier, Castañeda-Infante, Laura, Mouzo, Ricardo, Cao, Mercedes, Besada-Cerecedo, María L., Pan-Lizcano, Ricardo, Torra, Roser, Ortiz, Alberto, and de Sequera, Patricia

Abstract

Chronic kidney disease (CKD) of unknown etiology (CKDUE) is one of the main global causes of kidney failure. While genetic studies may identify an etiology in these patients, few studies have implemented genetic testing of CKDUE in population-based series of patients which was the focus of the GENSEN.

Published
2024
Full Text
View/download PDF

28. The kidney-skeletal muscle-heart axis in chronic kidney disease: implications for myokines.

Author

Quiroga B and Díez J

Abstract

Myokines are signalling moieties released by the skeletal muscle in response to acute and/or chronic exercise, which exert their beneficial or detrimental effects through paracrine and/or autocrine pathways on the own muscle and through endocrine pathways in many other organs (e.g. the heart). Interestingly, alterations in myokines have been described in patients with heart failure (HF) that are associated with adverse structural and functional left ventricular remodelling and poor cardiac outcomes. Recent experimental and clinical studies have shown that the muscle regulation of a number of myokines is altered in chronic kidney disease (CKD) thus representing a new molecular aspect of the pathophysiology of skeletal myopathy present in patients with CKD. Muscle dysregulation of myokines may contribute to a number of disorders in non-dialysis and dialysis patients with CKD, including the high risk of developing HF. This possibility would translate into a range of new diagnostic and therapeutic options. In fact, the measurement of circulating myokines opens their possible usefulness as biomarkers to personalize exercise training and pharmacological therapies for the prevetion and treatment of HF in patients with CKD and skeletal myopathy. This review will analyze information on some myokines that target the heart and are altered at the level of skeletal muscle and circulation in patients with CKD., (© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results